RU2018138510A3 - - Google Patents

Download PDF

Info

Publication number
RU2018138510A3
RU2018138510A3 RU2018138510A RU2018138510A RU2018138510A3 RU 2018138510 A3 RU2018138510 A3 RU 2018138510A3 RU 2018138510 A RU2018138510 A RU 2018138510A RU 2018138510 A RU2018138510 A RU 2018138510A RU 2018138510 A3 RU2018138510 A3 RU 2018138510A3
Authority
RU
Russia
Application number
RU2018138510A
Other versions
RU2018138510A (ru
RU2724469C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to RU2018138510A priority Critical patent/RU2724469C2/ru
Priority to TW108139053A priority patent/TW202031682A/zh
Priority to KR1020217016587A priority patent/KR20210084604A/ko
Priority to MA53186A priority patent/MA53186B2/fr
Priority to EP19880700.0A priority patent/EP3875486A4/en
Priority to JP2021523796A priority patent/JP2022506430A/ja
Priority to JOP/2021/0100A priority patent/JOP20210100A1/ar
Priority to SG11202104248UA priority patent/SG11202104248UA/en
Priority to MX2021005033A priority patent/MX2021005033A/es
Priority to CN201980087511.2A priority patent/CN113272329A/zh
Priority to PE2021000556A priority patent/PE20211731A1/es
Priority to UY0001038432A priority patent/UY38432A/es
Priority to AU2019373999A priority patent/AU2019373999A1/en
Priority to CA3117486A priority patent/CA3117486A1/en
Priority to PCT/RU2019/050205 priority patent/WO2020091634A1/ru
Priority to EA202191173A priority patent/EA202191173A1/ru
Priority to US17/288,234 priority patent/US20220089761A1/en
Priority to BR112021008326-0A priority patent/BR112021008326A2/pt
Priority to ARP190103167A priority patent/AR116937A1/es
Publication of RU2018138510A publication Critical patent/RU2018138510A/ru
Publication of RU2018138510A3 publication Critical patent/RU2018138510A3/ru
Application granted granted Critical
Publication of RU2724469C2 publication Critical patent/RU2724469C2/ru
Priority to CONC2021/0005178A priority patent/CO2021005178A2/es
Priority to ECSENADI202128958A priority patent/ECSP21028958A/es
Priority to IL282742A priority patent/IL282742A/en
Priority to CL2021001104A priority patent/CL2021001104A1/es
Priority to ZA2021/02874A priority patent/ZA202102874B/en
Priority to PH12021550991A priority patent/PH12021550991A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2018138510A 2018-10-31 2018-10-31 Моноклональное антитело, которое специфически связывается с cd20 RU2724469C2 (ru)

Priority Applications (25)

Application Number Priority Date Filing Date Title
RU2018138510A RU2724469C2 (ru) 2018-10-31 2018-10-31 Моноклональное антитело, которое специфически связывается с cd20
TW108139053A TW202031682A (zh) 2018-10-31 2019-10-29 特異性結合至ｃｄ２０的單株抗體
EA202191173A EA202191173A1 (ru) 2018-10-31 2019-10-30 Моноклональное антитело, которое специфически связывается с cd20
EP19880700.0A EP3875486A4 (en) 2018-10-31 2019-10-30 MONOCLONAL ANTIBODY THAT BINDS SPECIFICALLY TO CD20
JP2021523796A JP2022506430A (ja) 2018-10-31 2019-10-30 Ｃｄ２０に特異的に結合するモノクローナル抗体
JOP/2021/0100A JOP20210100A1 (ar) 2018-10-31 2019-10-30 جسم مضاد أحادي النسيلة يرتبط على وجه التحديد بـ cd20
SG11202104248UA SG11202104248UA (en) 2018-10-31 2019-10-30 Monoclonal antibody that specifically binds to cd20
MX2021005033A MX2021005033A (es) 2018-10-31 2019-10-30 Anticuerpo monoclonal que se une especificamente al antigeno cd20.
CN201980087511.2A CN113272329A (zh) 2018-10-31 2019-10-30 与cd20特异性结合的单克隆抗体
PE2021000556A PE20211731A1 (es) 2018-10-31 2019-10-30 Anticuerpo monoclonal que se une especificamente al antigeno cd20
UY0001038432A UY38432A (es) 2018-10-31 2019-10-30 Anticuerpo monoclonal que se une específicamente al antígeno cd20
AU2019373999A AU2019373999A1 (en) 2018-10-31 2019-10-30 Monoclonal antibody that specifically binds to CD20
KR1020217016587A KR20210084604A (ko) 2018-10-31 2019-10-30 Cd20에 특이적으로 결합하는 단일클론 항체
PCT/RU2019/050205 WO2020091634A1 (ru) 2018-10-31 2019-10-30 Моноклональное антитело, которое специфически связывается с cd20
MA53186A MA53186B2 (fr) 2018-10-31 2019-10-30 Anticorps monoclonal qui se lie spécifiquement à cd20
US17/288,234 US20220089761A1 (en) 2018-10-31 2019-10-30 Monoclonal antibody that specifically binds to cd20
BR112021008326-0A BR112021008326A2 (pt) 2018-10-31 2019-10-30 Anticorpo monoclonal, ácido nucleico, vetor de expressão, método para a produção de uma célula hospedeira, célula hospedeira, método para a produção de um anticorpo, composição farmacêutica, combinação farmacêutica, método para a inibição da atividade biológica de cd20, método para o tratamento de uma doença ou distúrbio e uso de um anticorpo
CA3117486A CA3117486A1 (en) 2018-10-31 2019-10-30 Monoclonal antibody that specifically binds to cd20
ARP190103167A AR116937A1 (es) 2018-10-31 2019-10-31 Anticuerpo monoclonal que se une específicamente al antígeno cd20
CONC2021/0005178A CO2021005178A2 (es) 2018-10-31 2021-04-22 Anticuerpo monoclonal que se une específicamente al antígeno cd20
ECSENADI202128958A ECSP21028958A (es) 2018-10-31 2021-04-22 Anticuerpo monoclonal que se une específicamente al antígeno cd20
IL282742A IL282742A (en) 2018-10-31 2021-04-28 A monoclonal antibody that binds uniquely to CD20
CL2021001104A CL2021001104A1 (es) 2018-10-31 2021-04-28 Anticuerpo monoclonal que se une específicamente al antígeno cd20
ZA2021/02874A ZA202102874B (en) 2018-10-31 2021-04-29 Monoclonal antibody that specifically binds to cd20
PH12021550991A PH12021550991A1 (en) 2018-10-31 2021-04-30 Monoclonal antibody that specifically binds to cd20

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2018138510A RU2724469C2 (ru) 2018-10-31 2018-10-31 Моноклональное антитело, которое специфически связывается с cd20

Publications (3)

Publication Number Publication Date
RU2018138510A RU2018138510A (ru) 2020-04-30
RU2018138510A3 true RU2018138510A3 (ru) 2020-04-30
RU2724469C2 RU2724469C2 (ru) 2020-06-23

Family

ID=70462324

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018138510A RU2724469C2 (ru) 2018-10-31 2018-10-31 Моноклональное антитело, которое специфически связывается с cd20

Country Status (25)

Country Link
US (1) US20220089761A1 (ru)
EP (1) EP3875486A4 (ru)
JP (1) JP2022506430A (ru)
KR (1) KR20210084604A (ru)
CN (1) CN113272329A (ru)
AR (1) AR116937A1 (ru)
AU (1) AU2019373999A1 (ru)
BR (1) BR112021008326A2 (ru)
CA (1) CA3117486A1 (ru)
CL (1) CL2021001104A1 (ru)
CO (1) CO2021005178A2 (ru)
EA (1) EA202191173A1 (ru)
EC (1) ECSP21028958A (ru)
IL (1) IL282742A (ru)
JO (1) JOP20210100A1 (ru)
MA (1) MA53186B2 (ru)
MX (1) MX2021005033A (ru)
PE (1) PE20211731A1 (ru)
PH (1) PH12021550991A1 (ru)
RU (1) RU2724469C2 (ru)
SG (1) SG11202104248UA (ru)
TW (1) TW202031682A (ru)
UY (1) UY38432A (ru)
WO (1) WO2020091634A1 (ru)
ZA (1) ZA202102874B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024025440A1 (en) * 2022-07-26 2024-02-01 Joint Stock Company "Biocad" Pharmaceutical composition of anti-cd20 antibody and use thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
FI891226A (fi) 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
KR920700674A (ko) 1989-03-21 1992-08-10 원본미기재 특정 t세포 집단에 의한 발명 반응으로부터 야기되는 질병에 대한 예방접종 및 방법
ES2112838T5 (es) 1989-07-19 2004-09-01 Connetics Corporation Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas.
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
CA2476166C (en) * 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
AU2011226858B2 (en) * 2002-12-16 2015-01-22 Genentech, Inc. Immunoglobulin variants and uses thereof
SI1572744T1 (sl) 2002-12-16 2010-09-30 Genentech Inc Imunoglobulinske variante in njihove uporabe
US20040202658A1 (en) 2003-04-09 2004-10-14 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to TNF-alpha inhibitor
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
RU2489166C2 (ru) 2006-04-09 2013-08-10 Джинентех, Инк. Применение антитела для лечения аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
WO2011100398A1 (en) * 2010-02-10 2011-08-18 Immunogen, Inc. Cd20 antibodies and uses thereof
CN102190728B (zh) * 2010-03-17 2014-07-02 永卓博济(上海)生物医药技术有限公司 一种人源化抗cd20单克隆抗体

Also Published As

Publication number Publication date
JP2022506430A (ja) 2022-01-17
WO2020091634A1 (ru) 2020-05-07
MX2021005033A (es) 2021-06-15
RU2018138510A (ru) 2020-04-30
JOP20210100A1 (ar) 2023-01-30
US20220089761A1 (en) 2022-03-24
CO2021005178A2 (es) 2021-04-30
UY38432A (es) 2020-05-29
CN113272329A (zh) 2021-08-17
IL282742A (en) 2021-06-30
ZA202102874B (en) 2022-06-29
AR116937A1 (es) 2021-06-30
CA3117486A1 (en) 2020-05-07
PE20211731A1 (es) 2021-09-06
RU2724469C2 (ru) 2020-06-23
EA202191173A1 (ru) 2021-07-28
PH12021550991A1 (en) 2021-10-04
MA53186A1 (fr) 2022-02-28
KR20210084604A (ko) 2021-07-07
CL2021001104A1 (es) 2021-12-03
MA53186B2 (fr) 2023-05-31
EP3875486A1 (en) 2021-09-08
SG11202104248UA (en) 2021-05-28
BR112021008326A2 (pt) 2021-08-31
TW202031682A (zh) 2020-09-01
ECSP21028958A (es) 2021-05-31
EP3875486A4 (en) 2022-08-03
AU2019373999A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
BR112021012222A2 (ru)
BR122022015534A2 (ru)
BR112020025288A2 (ru)
BR112021008873A2 (ru)
BR122022002075A2 (ru)
AT524834A2 (ru)
AT524874A5 (ru)
AU2018438767B1 (ru)
AT521543A3 (ru)
AT524961A5 (ru)
RU2018138510A3 (ru)
AT524266A2 (ru)
BR122022005529A2 (ru)
BR122022016585A2 (ru)
BR112020012832A2 (ru)
BR102018070765A2 (ru)
BR102018016915A2 (ru)
BE2018C025I2 (ru)
BR102018007062A2 (ru)
BR202018006247U2 (ru)
BR202018004136U2 (ru)
BR202018002487U2 (ru)
BR202018002069U2 (ru)
CN304435613S (ru)
CN304454781S (ru)